| Ytd | -68.59% | |
| 1y | -81.26% |
| Open | 1.62 | Prev Close | 1.60 | Low | 1.60 | High | 1.65 | Mkt Cap | 36.95M |
| Vol | 13.47K | Avg Vol | 52.91K | EPS | -0.51 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.49 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 2.12 | 200-d Avg | 3.83 | 1yr Est | 14.67 |
Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the comme
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest
Fiinu (AIM: BANK), the UK fintech group, rose over 6% to 4p on Friday after its Plugin Overdraft pla
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary share
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest S
Maxim Group analyst Anthony Vendetti maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and l
Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowe
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million t
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks C
BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business
Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production prog
This particular scent is widely regarded as one of the most valuable fragrance raw materials in the
Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positi
Nu Skin Enterprises (NYSE: NUS - Get Free Report) and BioHarvest Sciences (NASDAQ: BHST - Get Free R
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Scien
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Scien
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has received a 4.33 million NIS
BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and su
Grant will partially fund research to enable faster development, with a higher probability of succes
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Scien
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Scien
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration wit
The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong techni
Expanded sweetener molecule development program aims to broaden access to plant-based sweetening sol
BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million
BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.11) per share
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million-Advancement of
BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"),
BioHarvest Sciences (NASDAQ:BHST) sees FY2026 sales of $42.000 million-$48.000 million vs $48.432 mi
BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.10) per share
With Stage 1 now completed, BioHarvest is ready to advance to Stage 2, where cells stored in a propr
Roth Capital analyst Sean McGowan initiates coverage on BioHarvest Sciences (NASDAQ:BHST) with a
BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"),